Compare ORMP & OXLCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORMP | OXLCN |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | N/A |
| IPO Year | 2010 | 2010 |
| Metric | ORMP | OXLCN |
|---|---|---|
| Price | $4.63 | $24.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 211.6K | 2.3K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 2.76 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.67 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $2.09 | $23.93 |
| 52 Week High | $5.47 | $25.10 |
| Indicator | ORMP | OXLCN |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 49.64 |
| Support Level | $3.91 | $24.29 |
| Resistance Level | $5.10 | $24.66 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 7.61 | 55.88 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize portfolio's risk adjusted total return, and currently seek to achieve investment objective by investing in structured finance investments, specifically the equity and junior debt tranches of CLO vehicles, which are collateralized by a diverse portfolio of senior secured loans made to companies whose debt is unrated or is rated below investment grade (the Senior Loans) and, to a limited. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.